Europe Vacuum Blood Collection Tube Market Size, Share & Trends Analysis Report By Product Type (Serum Tubes, Plasma Separation Tubes, Heparin Tubes, EDTA Tubes), By Material (Plastic, Glass), By Country (U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux) and Forecast, 2026-2034

Europe Vacuum Blood Collection Tube Market Trends

Shift Toward Plastic, Safety Engineering and Faster Pre-Analytics

European laboratories are progressively emphasizing plastic tubes, engineered separators, safety blood-collection sets and faster specimen processing. EU manufacturing facilities produce tens of millions of specimen tubes monthly, while approximately 70–80% of regional consumption is supplied by EU-based production and 20–30% through imports.

Automation-compatible closures, rapid-clotting formulations and mechanical or gel separation technologies are gaining operational importance as laboratories target shorter turnaround times. Greiner Bio-One operates 28 locations, employed 2,651 people and generated EUR 637 million in 2025 sales, illustrating the industrial scale supporting pre-analytical innovation. A 2025 clinical evaluation also assessed a recently developed quick-clotting VACUETTE serum separator across 16 biochemical analytes.

Europe Vacuum Blood Collection Tube Market Drivers

High Recurring Diagnostic Volumes and Laboratory Automation

Routine chemistry, hematology, coagulation and metabolic testing create recurring tube consumption because each collected specimen typically requires dedicated additives and validated pre-analytical handling. EU facilities supply an estimated 70–80% of local specimen-tube consumption, leaving 20–30% supported by imports, while major manufacturing sites produce tens of millions of units monthly. Hospital networks increasingly prioritize standardized collection systems that reduce handling errors, support automated analyzers and improve high-volume laboratory workflows.

Europe Vacuum Blood Collection Tube Market Restraints

Regulatory Qualification and Procurement Pressure Increase Supplier Burden

IVDR compliance, hospital qualification, raw-material costs and centralized tendering constrain supplier flexibility. New supplier qualification can require approximately 12–18 months, while imported products account for roughly 20–30% of EU consumption. Competition is particularly price-intensive for standardized tubes, whereas specialty products must satisfy additive accuracy, sterile-packaging and documentation requirements.

Europe Vacuum Blood Collection Tube Market Opportunities

Safety-Engineered and Rapid-Processing Systems Expand Value Creation

Premium opportunities are emerging around safer venipuncture, rapid serum preparation and specialty additives. Europe retains approximately 70–80% domestic supply coverage, while major suppliers operate production and distribution networks spanning more than 100 countries. Greiner Bio-One alone reported EUR 637 million revenue and 2,651 employees in 2025, demonstrating the scale available for continued investment in safety-focused preanalytics and automated manufacturing.

Challenges in Europe Vacuum Blood Collection Tube Market

Maintaining Vacuum Integrity and Sample Quality Across Large Supply Networks

Manufacturers must maintain fill volume, vacuum integrity, additive concentration and separator consistency across production volumes reaching tens of millions of tubes monthly. EU supply represents approximately 70–80% of regional consumption, but the remaining 20–30% import requirement introduces logistics and documentation exposure. Quality failures can disrupt validated laboratory workflows, making manufacturing consistency and traceability central procurement criteria.

Europe Vacuum Blood Collection Tube Market Segmentation

The industry is segmented by product type, material, application, end user and distribution channel. Product data show serum tubes leading with approximately 29.1% of 2026 revenue, while plasma separation tubes contribute approximately 24.2%.

By Product Type

Serum tubes are the largest product category, increasing from USD 309.91 million in 2025 to USD 319.98 million in 2026 and USD 413.28 million by 2034 at 3.25% CAGR. Their position reflects extensive use across chemistry, serology and immunology workflows.

Others, including thrombin and trace-element tubes, record the fastest CAGR at 3.44%, reaching USD 80.89 million by 2034. Heparin and EDTA tubes also expand at 3.33% and 3.36%, respectively.

By Material

Plastic and glass constitute the principal material categories. Plastic is increasingly preferred for high-throughput environments because of break resistance, lower handling weight and compatibility with automated workflows; BD historically expanded its Vacutainer portfolio into plastic tube formats.

The supplied dataset does not provide separate material-level revenue or CAGR figures. Consequently, no unsupported numerical material forecast is assigned.

By Application

Applications include routine chemistry, blood sugar testing, coagulation testing, lipid profiling, infectious-disease testing and other laboratory procedures. Serum tubes—the leading product proxy for broad chemistry workflows—stand at USD 319.98 million in 2026 and expand at 3.25% CAGR.

No application-specific revenue or CAGR values are supplied; therefore, quantitative allocation across the six application categories is not inferred.

By End User

Hospitals, diagnostic laboratories, blood banks, ambulatory surgical centers and academic/research facilities form the principal customer groups. Their requirements emphasize standardized draw volumes, sample integrity and analyzer-compatible collection systems.

The supplied tables contain no end-user revenue or CAGR split. Quantitative dominance or fastest-growing end-user claims therefore cannot be calculated reliably from the mandatory dataset.

By Distribution Channel

Direct tenders, retail sales, online sales and distributors constitute the principal commercial channels. Large hospitals and laboratory networks commonly use centralized procurement, creating significant price competition for standardized tubes.

No channel-level market values or CAGR figures are supplied. Accordingly, numerical channel shares are not extrapolated beyond the mandatory dataset.

Europe Vacuum Blood Collection Tube Market Counties Outlook

U.K.

The United Kingdom records USD 220.72 million in 2026, approximately 20.1% of the regional total, and reaches USD 283.54 million by 2034 at 3.18% CAGR. Its contribution is supported by hospital laboratories, centralized diagnostics and established European manufacturing infrastructure.

Germany

Germany leads at USD 277.47 million in 2026, representing approximately 25.2%, and advances to USD 355.61 million by 2034 at 3.15% CAGR. Germany also hosts important European laboratory-consumables manufacturing capacity.

France

France contributes approximately 15.6%, with revenue of USD 171.92 million in 2026. The country reaches USD 220.84 million by 2034 at 3.18% CAGR, supported by routine chemistry and hospital diagnostics.

Spain

Spain represents approximately 8.0%, generating USD 88.13 million in 2026 and reaching USD 112.95 million by 2034 at 3.15% CAGR. Hospital and independent laboratory testing remain core consumption channels.

Italy

Italy accounts for approximately 13.0%, rising from USD 143.05 million in 2026 to USD 185.33 million in 2034. Its 3.29% CAGR exceeds several larger Western European countries.

Russia

Russia records USD 88.22 million in 2026, approximately 8.0% of the total. At 3.51% CAGR—the fastest among listed countries—it reaches USD 116.26 million by 2034.

Nordic

Nordic countries generate USD 55.00 million in 2026, approximately 5.0%, and reach USD 71.04 million by 2034 at 3.25% CAGR. Laboratory automation and standardized diagnostics support consumption.

Benelux

Benelux contributes approximately 5.0%, valued at USD 55.08 million in 2026 and USD 70.86 million by 2034 at 3.20% CAGR. The Netherlands and Belgium also function as important European logistics and medtech distribution hubs.

Top players in Europe Vacuum Blood Collection Tube Market

• Becton, Dickinson and Company
• Greiner Bio-One International GmbH
• SARSTEDT AG & Co. KG
• Terumo Corporation
• Sekisui Chemical Co., Ltd.
• Nipro Corporation
• Cardinal Health, Inc.
• FL Medical S.r.l.
• Improve Medical
• IntervacTechnology
• Thermo Fisher Scientific Inc.

Top Two Companies

• Becton, Dickinson and Company

BD maintains a leading competitive position through the Vacutainer platform, a broad portfolio spanning serum, plasma, EDTA and specialty collection products, and established European operations. Industry evidence identifies BD among the dominant EU suppliers, with the leading four-to-five vendors collectively estimated to serve 65–75% of regional specimen-tube requirements. An individual BD percentage is not reliably disclosed, so assigning a company-specific share would be unsupported.

• Greiner Bio-One International GmbH

Greiner Bio-One is a major Austria-headquartered preanalytics supplier with seven production sites across four continents and distribution in more than 100 countries. In 2025, the business reported EUR 637 million sales, 2,651 employees and 28 locations. Together with BD, Sarstedt, Terumo and other leading suppliers, it operates within the estimated 65–75% concentration held by the leading vendor group; an audited standalone European tube percentage is not publicly established.

Recent Developments in Europe Vacuum Blood Collection Tube Market

• 2026:Research using Portuguese blood-service data demonstrated optimization approaches achieving 86.1–90.0% demand fulfillment, highlighting increasing digital optimization of European blood-collection operations.
• 2025:Greiner Bio-One reported EUR 637 million in sales, 2,651 employees and 28 locations while emphasizing continued investment in medical and laboratory solutions.
• 2025:A clinical study published in March evaluated the recently developed VACUETTE CAT Serum Fast Separator Tube across 16 biochemical analytes and assessed analyte stability.
• 2025:Greiner Bio-One introduced the VACUETTE EasyClean Tourniquet in September, extending its pre-analytical blood-collection ecosystem.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 treated as historical years. Mandatory supplied country and product tables serve as the primary quantitative dataset for revenue, contribution and CAGR calculations. Secondary validation covers manufacturer disclosures, product documentation, industry supply-chain evidence and peer-reviewed research. Where the supplied dataset does not provide material, application, end-user, distribution-channel or company-specific percentages, values are intentionally not fabricated.